Perhaps no recent development in cardiology has aroused so much interest and controversy as the role of platelet-aggregation inhibitors in the prevention of reinfarction and sudden death in patients with heart disease. Clinical trials of aspirin and other antiplatelet agents are reviewed. Despite their equivocal results, a pragmatic approach to antithrombotic prophylaxis is suggested.